{
  "success": true,
  "pagesUsed": [
    47,
    48,
    49
  ],
  "modelUsed": "gemini-2.5-pro",
  "eligibility": {
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Age and Menopausal Status",
        "text": "Women 18 years of age or older, who are either:\n\nPostmenopausal, as defined by at least one of the following criteria:\n\nAge 60 years;\n\nAge <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and FSH level within the laboratory’s reference range for postmenopausal females;\n\nDocumented bilateral oophorectomy;\n\nMedically confirmed ovarian failure.\nOR\n\nPre/peri-menopausal, ie, not meeting the criteria for being postmenopausal.\n\nPre/perimeopausal women can be enrolled if amenable to be treated with the LHRH agonist goserelin. Patients must have commenced treatment with goserelin or an alternative LHRH agonist at least 4 weeks prior to randomization. But, if patients have received an alternative LHRH agonist prior to study entry, they must switch to goserelin for the duration of the trial.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Diagnosis of Breast Cancer",
        "text": "Histologically or cytologically proven diagnosis of breast cancer with evidence of metastatic or locally advanced disease, not amenable to resection or radiation therapy with curative intent.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "ER/PR Status",
        "text": "Documentation of ER-positive and/or PR-positive tumor (1% positive stained cells) based on most recent tumor biopsy (unless bone-only disease, see below) utilizing an assay consistent with local standards.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "HER2 Status",
        "text": "Documented HER2-negative tumor based on local testing on most recent tumor biopsy: HER2-negative tumor is determined as immunohistochemistry score 0/1+ or negative by in situ hybridization (FISH/CISH/SISH/DISH) defined as a HER2/CEP17 ratio <2 or for single probe assessment a HER2 copy number <4.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Prior Therapy Requirements",
        "text": "Patients must satisfy the following criteria for prior therapy: \n\nProgressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.\nOR\n\nProgressed while on or within 1 month after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancer if postmenopausal, or prior endocrine treatment for advanced/metastatic breast cancer if pre- or perimenopausal. \nOne previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Tumor Tissue Sample Provision",
        "text": "Except where prohibited by local regulations, all patients must agree to provide and have available a formalin-fixed paraffin embedded (FFPE) tissue biopsy sample taken at the time of presentation with recurrent or metastatic disease. A de novo biopsy is required if no archived tissue taken at the time of presentation with recurrent/metastatic disease is available. The sole exception is those patients with bone only disease for whom provision of previous archival tissue only is acceptable. Patients who had surgery within the last 3 years (but without neoadjuvant chemotherapy prior to surgery) and relapsed while receiving adjuvant therapy may provide a tumor specimen from that surgery.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Disease Measurability",
        "text": "Measurable disease as defined by RECIST version 1.1, or bone-only disease.  Patients with bone-only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by CT or MRI. Patients with bone-only disease and blastic-only metastasis are not eligible. Tumor lesions previously irradiated or subjected to other loco regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "ECOG Performance Status",
        "text": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Adequate Organ and Marrow Function",
        "text": "Adequate organ and marrow function defined as follows: \n\nANC 1,500/mm3 (1.5 x 109/L);\n\nPlatelets 100,000/mm3 (100 x 109/L);\n\nHemoglobin 9 g/dL (90 g/L);\n\nSerum creatinine 1.5 x ULN or estimated creatinine clearance 60 ml/min as calculated using the method standard for the institution;\n\nTotal serum bilirubin 1.5 x ULN (<3ULN if Gilbert’s disease);\n\nAST and/or ALT 3 x ULN (5.0 x ULN if liver metastases present);",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion",
        "name": "Age and Menopausal Status",
        "nextId": "ec_2"
      },
      {
        "id": "ec_2",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion",
        "name": "Diagnosis of Breast Cancer",
        "previousId": "ec_1",
        "nextId": "ec_3"
      },
      {
        "id": "ec_3",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion",
        "name": "ER/PR Status",
        "previousId": "ec_2",
        "nextId": "ec_4"
      },
      {
        "id": "ec_4",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion",
        "name": "HER2 Status",
        "previousId": "ec_3",
        "nextId": "ec_5"
      },
      {
        "id": "ec_5",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion",
        "name": "Prior Therapy Requirements",
        "previousId": "ec_4",
        "nextId": "ec_6"
      },
      {
        "id": "ec_6",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion",
        "name": "Tumor Tissue Sample Provision",
        "previousId": "ec_5",
        "nextId": "ec_7"
      },
      {
        "id": "ec_7",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion",
        "name": "Disease Measurability",
        "previousId": "ec_6",
        "nextId": "ec_8"
      },
      {
        "id": "ec_8",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion",
        "name": "ECOG Performance Status",
        "previousId": "ec_7",
        "nextId": "ec_9"
      },
      {
        "id": "ec_9",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion",
        "name": "Adequate Organ and Marrow Function",
        "previousId": "ec_8"
      }
    ],
    "summary": {
      "inclusionCount": 9,
      "exclusionCount": 0,
      "totalCount": 9
    },
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9"
      ],
      "instanceType": "StudyDesignPopulation",
      "description": "Target population defined by eligibility criteria"
    }
  },
  "rawResponse": {
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "name": "Age and Menopausal Status",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_2",
        "name": "Diagnosis of Breast Cancer",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_3",
        "name": "ER/PR Status",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_4",
        "name": "HER2 Status",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_5",
        "name": "Prior Therapy Requirements",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_6",
        "name": "Tumor Tissue Sample Provision",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_7",
        "name": "Disease Measurability",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_8",
        "name": "ECOG Performance Status",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_9",
        "name": "Adequate Organ and Marrow Function",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion"
      }
    ],
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Age and Menopausal Status",
        "text": "Women 18 years of age or older, who are either:\n\nPostmenopausal, as defined by at least one of the following criteria:\n\nAge 60 years;\n\nAge <60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and FSH level within the laboratory’s reference range for postmenopausal females;\n\nDocumented bilateral oophorectomy;\n\nMedically confirmed ovarian failure.\nOR\n\nPre/peri-menopausal, ie, not meeting the criteria for being postmenopausal.\n\nPre/perimeopausal women can be enrolled if amenable to be treated with the LHRH agonist goserelin. Patients must have commenced treatment with goserelin or an alternative LHRH agonist at least 4 weeks prior to randomization. But, if patients have received an alternative LHRH agonist prior to study entry, they must switch to goserelin for the duration of the trial.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Diagnosis of Breast Cancer",
        "text": "Histologically or cytologically proven diagnosis of breast cancer with evidence of metastatic or locally advanced disease, not amenable to resection or radiation therapy with curative intent.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "ER/PR Status",
        "text": "Documentation of ER-positive and/or PR-positive tumor (1% positive stained cells) based on most recent tumor biopsy (unless bone-only disease, see below) utilizing an assay consistent with local standards.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "HER2 Status",
        "text": "Documented HER2-negative tumor based on local testing on most recent tumor biopsy: HER2-negative tumor is determined as immunohistochemistry score 0/1+ or negative by in situ hybridization (FISH/CISH/SISH/DISH) defined as a HER2/CEP17 ratio <2 or for single probe assessment a HER2 copy number <4.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Prior Therapy Requirements",
        "text": "Patients must satisfy the following criteria for prior therapy: \n\nProgressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.\nOR\n\nProgressed while on or within 1 month after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancer if postmenopausal, or prior endocrine treatment for advanced/metastatic breast cancer if pre- or perimenopausal. \nOne previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Tumor Tissue Sample Provision",
        "text": "Except where prohibited by local regulations, all patients must agree to provide and have available a formalin-fixed paraffin embedded (FFPE) tissue biopsy sample taken at the time of presentation with recurrent or metastatic disease. A de novo biopsy is required if no archived tissue taken at the time of presentation with recurrent/metastatic disease is available. The sole exception is those patients with bone only disease for whom provision of previous archival tissue only is acceptable. Patients who had surgery within the last 3 years (but without neoadjuvant chemotherapy prior to surgery) and relapsed while receiving adjuvant therapy may provide a tumor specimen from that surgery.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Disease Measurability",
        "text": "Measurable disease as defined by RECIST version 1.1, or bone-only disease.  Patients with bone-only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by CT or MRI. Patients with bone-only disease and blastic-only metastasis are not eligible. Tumor lesions previously irradiated or subjected to other loco regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "ECOG Performance Status",
        "text": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Adequate Organ and Marrow Function",
        "text": "Adequate organ and marrow function defined as follows: \n\nANC 1,500/mm3 (1.5 x 109/L);\n\nPlatelets 100,000/mm3 (100 x 109/L);\n\nHemoglobin 9 g/dL (90 g/L);\n\nSerum creatinine 1.5 x ULN or estimated creatinine clearance 60 ml/min as calculated using the method standard for the institution;\n\nTotal serum bilirubin 1.5 x ULN (<3ULN if Gilbert’s disease);\n\nAST and/or ALT 3 x ULN (5.0 x ULN if liver metastases present);",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "plannedMinimumAge": "P18Y",
      "plannedSex": [
        {
          "code": "Female",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Female"
        }
      ],
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9"
      ],
      "instanceType": "StudyDesignPopulation"
    }
  }
}